🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: RSVPreF3 OA vaccine

Found 18 matching trials

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

PHASE3

The aim of this study is to assess the immunogenicity, safety and reactogen...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-10-14

Trial ID

NCT05568797

Treatments Being Tested

RSVPreF3 OA vaccine FLU vaccine

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

PHASE3

This study will evaluate the efficacy of the RSVPreF3 OA investigational va...

Status

Completed

Location

GSK Investigational Site

Start Date

2021-05-25

Trial ID

NCT04886596

Treatments Being Tested

Placebo RSVPreF3 OA vaccine

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

PHASE3

The purpose of this study is to assess the immunogenicity, safety and react...

Status

Completed

Location

GSK Investigational Site

Start Date

2021-04-27

Trial ID

NCT04841577

Treatments Being Tested

RSVPreF3 OA investigational vaccine FLU-QIV

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

PHASE3

The purpose of this study is to assess the ability of RSVPreF3 OA investiga...

Status

Completed

Location

GSK Investigational Site

Start Date

2023-05-26

Trial ID

NCT05879107

Treatments Being Tested

RSVPreF3 OA investigational vaccine PCV20

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

PHASE3

To assess the ability of RSVPreF3 OA investigational vaccine to generate an...

Status

Completed

Location

GSK Investigational Site

Start Date

2023-07-28

Trial ID

NCT05966090

Treatments Being Tested

RSVPreF3 OA investigational vaccine HZ/su vaccine

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

PHASE3

The study will evaluate the immune response of the RSVPreF3 OA investigatio...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2025-10-29

Trial ID

NCT07220109

Treatments Being Tested

RSVPreF3 OA vaccine Placebo

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

PHASE3

This study is assessing the immunogenicity, safety and reactogenicity of th...

Status

Completed

Location

GSK Investigational Site

Start Date

2024-04-29

Trial ID

NCT06374394

Treatments Being Tested

RSVPreF3 OA investigational vaccine COVID-19 mRNA vaccine

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

PHASE3

The purpose of the current study is to evaluate the immune response of the ...

Status

Completed

Location

GSK Investigational Site

Start Date

2024-08-05

Trial ID

NCT06551181

Treatments Being Tested

RSVPreF3 OA investigational vaccine Placebo (Saline solution)

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

PHASE2

The purpose of this study is to evaluate the immunogenicity, safety, and re...

Status

Completed

Location

GSK Investigational Site

Start Date

2023-07-28

Trial ID

NCT05921903

Treatments Being Tested

RSVPreF3 OA Investigational Vaccine

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

PHASE3

The aim of this study is to demonstrate the non-inferiority (NI) of the imm...

Status

Completed

Location

Multiple Locations

Start Date

2022-10-28

Trial ID

NCT05590403

Treatments Being Tested

RSVPreF3 OA investigational vaccine Placebo

Previous Next